20.00 USD
↘ 0.41 (2.01%)AT CLOSE (11:59 AM EDT)
Bicara Therapeutics Inc. Common Stock
BCAXNASDAQ • USD
20.01
↗ 0.00 (0.02%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
20.01
↗ 0.00 (0.02%)
Market: CLOSED
Open?$20.28
High?$20.42
Low?$19.95
Prev. Close?$20.41
Volume?356.2K
Avg. Volume?493.2K
VWAP?$20.11
Rel. Volume?0.72x
Bid / Ask
Bid?$16.75 × 100
Ask?$23.98 × 100
Spread?$7.23
Midpoint?$20.37
Valuation & Ratios
Market Cap?1.3B
Shares Out?65.7M
Float?29.8M
Float %?47.0%
P/E Ratio?N/A
P/B Ratio?2.56
EPS?-$2.39
Dividend?0.00%
Ex-Dividend?N/A
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $20.00. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest BCAX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Themes
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?5
Piotroski F-Score?0/9Weak
Altman Z-Score?18.90Safe
Confidence?41%Low
Short InterestSqueeze Risk
Short % of Float?33.09%Squeeze Risk
Short Interest?9.8M
Days to Cover?17.3
Free Float29.8M
Avg Daily Volume568.9K
Settlement Date2026-05-15
Financial Health
Current Ratio?13.85Strong
Quick Ratio?13.85Strong
Cash Ratio?8.22Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.56CHEAP▾
Peers100
S&P63
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-5.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-30.6%WEAK▾
S&P6
ROA?-28.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-116576000
Enterprise Value?$990.6M
Fundamentals ratios updated end of day